Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, outlines the role of TACE with systemic therapy in hepatocellular carcinoma (HCC)
David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, tells us about reliable biomarkers that should be used when treating esophagogastric cancers
Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, offers opinion on whether sorafenib is effective and tolerable in combination with I-O in newly diagnosed hepatocellular carcinoma (HCC)
David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, considers the role of evidence-based medicine and the incorporation of I-O into esophagogastric cancer treatment algorithms
Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, shares what physicians should know about current treatment options and sequencing of TKIs in hepatocellular carcinoma (HCC)
David Ilson, MD, PhD, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in HER2+ mEGA
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, on the effectiveness of the combination of pembrolizumab, trastuzumab, capecitabine and oxaliplatin in HER2+ metastatic esophagogastric adenocarcinoma (mEGA)
Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, considers how combined checkpoint inhibition could potentially change treatment algorithms in advanced hepatocellular carcinoma (HCC) and biliary tract carcinoma
David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, on how pembrolizumab compares with chemotherapy as a 2nd line therapy for advanced esophageal cancer
Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA, considers the role of systemic therapy in the management of hepatocellular carcinoma (HCC)
David Ilson, MD, PhD, shares results from the TAGS trial presented at GI 2019
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, tells us about the results of the Phase 3 study investigating TAS-102 in metastatic gastric cancer presented the 2019 Gastrointestinal Cancers Symposium
Rachna Shroff, MD, gives her take on pre-operative therapy in resectable pancreatic cancer
Dr. Shroff, Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, considers the role of pre-operative therapy in resectable pancreatic cancer
Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, offers his opinion on whether physicians are likely to dose escalate with regorafenib when treating colorectal cancer (CRC)
Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma
Dr. Shroff, Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, on the evolving treatment landscape of hepatocellular carcinoma (HCC), specifically regarding the use of TKIs in managing the disease
Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, provides opinion on utilizing TKIs in the management of hepatocellular carcinoma (HCC)
Rachna Shroff, MD, discusses how BRAF mutations figure into cholangiocarcinoma treatment
Dr. Shroff, Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, elaborates on how BRAF mutations figure into treatment algorithms for cholangiocarcinoma
Rachna Shroff, MD, expands on targeted therapies in the treatment of cholangiocarcinoma
Dr. Shroff, Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, tells us how targeted therapies are being integrated into the treatment of cholangiocarcinoma
Richard Kim, MD, on the role of BRAF mutations in treatment of cholangiocarcinoma
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, explains how the BRAF mutation figures into treatment algorithms for cholangiocarcinoma
Richard Kim, MD, regarding targeted therapies in treatment of cholangiocarcinoma
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, tells us how targeted therapies are being integrated into the treatment of cholangiocarcinoma
Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC
Dr. Zhu, Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, considers whether sorafenib is tolerable in combination with I-O in newly diagnosed hepatocellular carcinoma (HCC) patients
Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC
Dr. Zhu, Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, provides opinion on what physicians should know about sequencing TKIs in hepatocellular carcinoma (HCC) patients
Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC
Dr. Zhu, Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, considers how checkpoint inhibitors could potentially change treatment algorithms in advanced hepatocellular carcinoma (HCC)
Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, shares his impression of the CCTG CO.26 trial comparing durvalumab plus tremelimumab and best supportive care (BSC) versus BSC in advanced refractory colorectal cancer (CRC)
Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, on the takeaways from the 2019 Gastrointestinal Cancers Symposium regarding treatment of biliary tract cancers
Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, considers whether the results of ReDOS study have allowed for more effective dosing of regorafenib in the management of advanced colorectal cancer (CRC) patients
Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, shares the latest in identifying valid biomarkers in the treatment of hepatocellular carcinoma (HCC)
Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, shares details regarding patient selection and treatment algorithms in the management of 2nd and 3rd line colorectal cancer patients
Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, tells us whether circulating tumor DNA (ctDNA) is a valid surrogate for minimal residual disease (MRD) or treatment response in colorectal cancer
Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, on whether circulating tumor DNA (ctDNA) is a valid surrogate for minimal residual disease (MRD) or treatment response in colorectal cancer
Alan Venook, MD, discusses next generation sequencing and mCRC treatment
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, provides opinion on how next generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC) patients
Axel Grothey, MD, elaborates on next generation sequencing and mCRC
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, explains how next generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC) patients
Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, explains how neoadjuvant chemotherapy with gemcitabine and S-1 compares with upfront surgery for resectable pancreatic cancer
Philip Philip MD, PhD, FRCP, on promising novel therapies for pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, discusses the most promising novel therapies in the pipeline for pancreatic cancer
Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, considers whether physicians are more likely to use regorafenib and dose escalate for hepatocellular carcinoma (HCC) patients as a result of the ReDOS study
Philip Philip MD, PhD, FRCP, provides opinion on NGS and BRCA gene testing in pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, on whether he recommends next generation sequencing (NGS) or BRCA gene testing for pancreatic cancer patients
Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, explains how stereotactic body radiation therapy (SBRT) is being used to treat early stage hepatocellular carcinoma (HCC)
Philip Philip MD, PhD, FRCP, considers molecular subtyping of pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, describes the good news and the bad news regarding molecular subtyping of pancreatic cancer
Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania tells us what physicians should know about current treatment options and sequencing TKIs in hepatocellular carcinoma (HCC)
Philip Philip MD, PhD, FRCP, on screening patients at high risk for pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, provides opinion on whether we should routinely screen patients at high risk for pancreatic cancer
Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, considers whether systemic therapy still plays a role in the management of hepatocellular carcinoma (HCC)
Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, shares thoughts on genetic testing in newly diagnosed metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRC
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, explains how checkpoint inhibitors are impacting treatment algorithms in metastatic colorectal cancer (mCRC)
Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute offers opinion on whether checkpoint inhibitors will be successful in improving outcomes for adjuvant colorectal cancer (CRC) patients
Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, considers how next generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC) patients
Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, tells us how he manages 2nd and 3rd line metastatic colorectal cancer (mCRC) patients and shares some of the drivers of treatment choice
Howard Hochster, MD, on the management of mCRC patients receiving regorafenib
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, discusses the results of the ReDose study and the management of metastatic colorectal cancer (mCRC) patients receiving regorafenib
Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, considers whether the results of the ReDOS study may make dosing of regorafenib more tolerable for metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, describes how he manages 2nd and 3rd line metastatic colorectal cancer (mCRC) patients
Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, discusses the BEACON study investigating the role of encorafenib, binimetinib and cetuximab in patients with BRAF mutated metastatic colorectal cancer (mCRC)
Howard Hochster, MD, regarding the role of genetic testing in mCRC
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, elaborates on genetic testing in newly diagnosed metastatic colorectal cancer (mCRC) patients and how these tests figure into treatment decisions
Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting
Dr. Mallick discusses some of the advances in the treatment of colorectal cancer coming out of the 2018 ASCO Annual Meeting
Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms
Dr. Mallick explains how tumor-sidedness impacts her colorectal cancer (CRC) treatment algorithms
Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms
Dr. Mallick tells us how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms
Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC
Dr. Mallick comments on the outcomes of the Checkmate 142 study looking ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients
Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC
Dr. Mallick elaborates on the patient type and setting where vemurafenib has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment
Dr. Mallick explains how the stage of colorectal cancer (CRC) and the mismatch repair status impact treatment algorithms
Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer
Dr. Mallick shares her thoughts on the headline “Immunotherapy Now Standard for Some Patients With Colorectal Cancer”
John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”
Dr. Leighton offers opinion on the headline “Immunotherapy Now Standard for Some Patients With Colorectal Cancer” coming out of the 2018 ASCO Annual Meeting
John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms
Dr. Leighton discusses whether tumor sidedness impacts colorectal cancer treatment algorithms
John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC
Dr. Leighton elaborates on the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC
Dr. Hochster provides perspective on the outcomes of the PRODIGY7 study in metastatic colorectal cancer patients using heated single agent oxaliplatin after surgery
Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018
Dr. Hochster regarding the effectiveness of maintenance 5FU/LV following FOLFOX + panitumumab induction in metastatic colorectal cancer patients
Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC
Dr. Hochster discusses the outcomes of the ECOG-7208 study in 2nd line metastatic colorectal cancer (mCRC) patients
Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"
Dr. Goldberg provides opinion on the headline, "Immunotherapy Now Standard for Some Patients With Colorectal Cancer" coming out of the 2018 ASCO Annual Meeting
Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients
Dr. Goldberg tells us about the outcomes the PRODIGY7 study in metastatic colorectal cancer (mCRC) patients using heated single agent oxaliplatin after surgery
Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms
Dr. Benson, Professor of Medicine, Northwestern University, on how tumor-sidedness impacts colorectal cancer treatment algorithms
Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC
Dr. Benson, Professor of Medicine, Northwestern University, the role of I-O and immunotherapy combinations when treating colorectal cancer
Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients
Dr. Benson, Professor of Medicine, Northwestern University, discusses what molecular markers are most important to test for when treating colorectal cancer patients
